Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid

被引:446
作者
Craig, WA
机构
[1] Univ Wisconsin, Madison, WI 53705 USA
[2] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA
关键词
D O I
10.1016/S0891-5520(03)00065-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pharmacodynamics (PDs) deals with the relationship between measures of drug exposure and the antimicrobial effect. Although different antimicrobials have been shown to vary in both their killing pattern and the presence and duration of persistent effects, drugs can still be divided into three major groups. The first group includes antibacterials that induce concentration-dependent killing and produce moderate to prolonged persistent effects. The second group is virtually the opposite of first group in that these drugs exhibit primarily time-dependent killing and produce minimal or no persistent effects with most organisms. The third and last group includes drugs that also have time-dependent killing but differ from the second group in that they produce moderate to prolonged persistent effects. This article focuses on the pharmacodynamics for beta-lactams, glycopeptides, and linezolid.
引用
收藏
页码:479 / +
页数:24
相关论文
共 101 条
[1]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[2]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[3]   In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379
[4]  
ANDES D, 1994, 4 INT C ANT AG CHEM, P147
[5]   Pharmacokinetics and pharmacodynamics of antibiotics in meningitis [J].
Andes, DR ;
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (03) :595-+
[6]  
ANDES DR, 1995, 35 INT C ANT AG CHEM, P12
[7]  
ANDES DR, 2001, 41 INT C ANT AG CHEM, P26
[8]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[9]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[10]   RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].
BODEY, GP ;
KETCHEL, SJ ;
RODRIGUEZ, V .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616